Drugs / PC-SOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03995732 | Jun 2019 → Oct 2020 | myocardial infarction | Beijing Tide Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PC-SOD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03995732 ↗ |
| Known as | Phosphatidyl Choline Cu/Zn Superoxide Dismutase | “Phosphatidyl Choline Cu/Zn Superoxide Dismutase (PC-SOD) for Injection” NCT03995732 ↗ |
| Route | Intravenous | “PC-SOD 40 mg dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.” NCT03995732 ↗ |